# EDGAR Filing Document

**Accession Number:** 0002022416
**File Stem:** 0001178913-26-002805
**Filing Date:** 2026-5
**Character Count:** 39294
**Document Hash:** 24ddff6049f92e16deb5c4452975ad4d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001178913-26-002805.hdr.sgml**: 20260519

**ACCESSION NUMBER**: 0001178913-26-002805

**CONFORMED SUBMISSION TYPE**: 10-K/A

**PUBLIC DOCUMENT COUNT**: 17

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260519

**DATE AS OF CHANGE**: 20260519

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Silexion Therapeutics Corp
- **CENTRAL INDEX KEY:** 0002022416
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-K/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42253
- **FILM NUMBER:** 26998609

**BUSINESS ADDRESS:**
- **STREET 1:** 12 ABBA HILLEL ROAD
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250606
- **BUSINESS PHONE:** 972-8-6286005

**MAIL ADDRESS:**
- **STREET 1:** 12 ABBA HILLEL ROAD
- **CITY:** RAMAT GAN
- **STATE:** L3
- **ZIP:** 5250606

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Biomotion Sciences
- **DATE OF NAME CHANGE:** 20240506

?xml version='1.0' encoding='ASCII'? Silexion Therapeutics Corp - 2022416 - 2026

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

### FORM 10-K/A
Amendment No. 1

☒ **ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES**

#### EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2025

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES**

For the transition period from _______________ to _______________

Commission File Number **001-39157**

![image0.jpg](image0.jpg)

### Silexion Therapeutics Corp
(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Cayman Islands** | **001-42253** | **N/A** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (IRS Employer<br>Identification No.) |

---

#### 12 Abba Hillel Road Ramat-Gan, Israel 5250606
(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: **+972-3 756-4999**

**Not Applicable**

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading<br>Symbol(s) | Name of each exchange on<br>which registered |
| **Ordinary shares, par value $0.0135 per share** | **SLXN** | **The Nasdaq Stock Market LLC** |
| **Warrants exercisable for ordinary shares at an exercise price of $1,552.50 per share**  | **SLXNW**  | **The Nasdaq Stock Market LLC** |

---

Securities registered pursuant to Section 12(g) of the Act: None

------

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.

Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

As of June 30, 2025 (the last business day of the registrant's most recently completed second fiscal quarter), the aggregate market value of the registrant's ordinary shares held by non-affiliates (based on 8,172,750 ordinary shares held by non-affiliates as of that date and an $0.81 closing price of the ordinary shares on Nasdaq on that date (neither of which reflects the subsequent 1-for-15 reverse share split effected by the registrant on July 29, 2025) was $6,619,600.

As of March 10, 2026, 3,330,785 ordinary shares, par value $0.0135 per share, were issued and outstanding.

Documents Incorporated by Reference: None.

------

#### EXPLANATORY NOTE
This Amendment No. 1 on Form 10-K/A (this "**Amendment**") to the Annual Report on Form 10-K of Silexion Therapeutics Corp (the "**Company**", "**we**", "**us**" or "**our**") for the fiscal year ended December 31, 2025, originally filed with the U.S. Securities and Exchange Commission (the "**SEC**") on March 17, 2026 (the "**Original 10-K**"), is being filed solely to amend and restate Part II "Item 9A. Controls and Procedures" to correct typographical errors whereby the date as of which the Company's management evaluated the effectiveness of our internal control over financial reporting is stated as December 31, 2024 whereas that evaluation was actually carried out as of December 31, 2025. Those typographical errors are corrected in this Amendment.

This Amendment contains only the cover page, this explanatory note, the complete text of Item 9A, the exhibit list, a signature page and the certifications of the Company's principal executive and financial and accounting officers under the Sarbanes Oxley Act of 2002, as amended.

Other than as expressly set forth herein (including updated versions of Exhibits 3.5 and 10.5.2 listed in the exhibit index, which reflect updated versions of matters included in the Original 10-K that have been approved by our shareholders since the filing of the Original 10-K), this Amendment does not, and does not purport to, amend, update or restate the information in the Original 10-K or reflect any events that have occurred after the Original 10-K was filed. Information not affected by this Amendment remains unchanged and reflects the disclosures made at the time as of which the Original 10-K was filed. This Amendment should be read together with the Original 10-K and the Company's other filings with the SEC.

------

#### Item 9A. Controls and Procedures.

#### Evaluation of Disclosure Controls and Procedures
We maintain "disclosure controls and procedures" as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

As of the end of the period covered by this Annual Report, we carried out an evaluation, under the supervision and with the participation of our senior management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rules 13a-15(b) and 15d-15(b). Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Annual Report.

#### Management's Report on Internal Control over Financial Reporting; Attestation Report of the Registered Public Accounting Firm.
Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Under the supervision and with the participation of our management, including our principal executive officers and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2025, based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013). Based on this evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2025.

We are an emerging growth company, and are furthermore neither an accelerated filer nor a large accelerated filer, in each case as defined in Rule 12b-2 under the Exchange Act. Therefore, we are not required under Section 202 of the Sarbanes-Oxley Act (and the SEC rules and regulations thereunder) to provide an attestation report on management's assessment of our internal control over financial reporting from a registered public accounting firm in this Annual Report.

#### Changes in Internal Control over Financial Reporting
Based on the evaluation conducted by our senior management, including our Chief Executive Officer and Chief Financial Officer, we have concluded that there has been no change that occurred during the three-month period ended December 31, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

------

#### PART IV

#### Item 15 . Exhibits and Financial Statement Schedules
(a) The following documents were filed as part of the Original 10-K:

(1) Our financial statements as of, and for the year ended December 31, 2025, which were included in the "F-" pages of the Original 10-K.

(3) The exhibits are listed in the following Exhibit Index:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [3.1](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex3-1_silexion.htm) | [Amended and Restated Memorandum and Articles of Association of Silexion Therapeutics Corp (formerly Biomotion Sciences) (incorporated by reference to Exhibit 3.1 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on August 21, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex3-1_silexion.htm) |
| [3.2](https://www.sec.gov/Archives/edgar/data/2022416/000117891324003866/exhibit_3-1.htm) | [Ordinary Resolution Effecting 1-for-9 Reverse Share Split to Share Capital of Silexion Therapeutics Corp (incorporated by reference to Exhibit 3.1 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on November 29, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000117891324003866/exhibit_3-1.htm) |
| [3.3](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002515/exhibit_3-1.htm) | [Ordinary Resolution Effecting 1-for-15 Reverse Share Split to Share Capital of Silexion Therapeutics Corp (incorporated by reference to Exhibit 3.1 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on July 29, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002515/exhibit_3-1.htm) |
| [3.4](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002985/exhibit_3-1.htm) | [Ordinary Resolution Approving Increase in Authorized Share Capital to $121,500 (9,000,000 ordinary shares, par value $0.0135) (incorporated by reference to Exhibit 3.1 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on August 19, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002985/exhibit_3-1.htm) |
| [3.5](https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/exhibit_3-1.htm) | [Ordinary Resolution Approving Increase in Authorized Share Capital to $796,500 (59,000,000 ordinary shares, par value $0.0135) (incorporated by reference to Exhibit 3.1 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on May 5, 2026)](https://www.sec.gov/Archives/edgar/data/2022416/000117891326002393/exhibit_3-1.htm) |
| [4.1\*](https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/exhibit_4-1.htm) | [Description of Securities of Silexion Therapeutics Corp registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended](https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/exhibit_4-1.htm) |
| [4.2](https://www.sec.gov/Archives/edgar/data/1835416/000121390021010849/ea136177ex4-1_moringaacq.htm) | [Warrant Agreement, dated February 19, 2021, by and between Moringa Acquisition Corp and Continental Stock Transfer & Trust Company, as warrant agent (incorporated by reference to Exhibit 4.1 to Moringa Acquisition Corp's Current Report on Form 8-K, filed with the SEC on February 22, 2021)](https://www.sec.gov/Archives/edgar/data/1835416/000121390021010849/ea136177ex4-1_moringaacq.htm) |
| [4.3](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex4-1_silexion.htm) | [Assignment, Assumption and Amendment Agreement, dated as of August 15, 2024, by and among Moringa Acquisition Corp, Silexion Therapeutics Corp (formerly known as Biomotion Sciences) and Continental Stock Transfer & Trust Company (incorporated by reference to Exhibit 4.1 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on August 21, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex4-1_silexion.htm) |
| [4.4](https://www.sec.gov/Archives/edgar/data/2022416/000117891324003866/exhibit_4-1.htm) | [Warrant Adjustment Notice, dated November 29, 2024, in respect of 1-for-9 Reverse Share Split of Silexion Therapeutics Corp (incorporated by reference to Exhibit 4.1 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on November 29, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000117891324003866/exhibit_4-1.htm) |
| [4.5](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002515/exhibit_4-1.htm) | [Warrant Adjustment Notice, dated July 29, 2025, in respect of 1-for-15 Reverse Share Split of Silexion Therapeutics Corp (incorporated by reference to Exhibit 4.1 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on July 29, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002515/exhibit_4-1.htm) |
| [10.1](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-4_silexion.htm) | [Amended and Restated Registration Rights and Lock-Up Agreement, dated August 14, 2024 and effective as of the Closing Date, by and among Silexion Therapeutics Corp (formerly known as Biomotion Sciences), Moringa Acquisition Corp, Moringa Sponsor, L.P., the distributees of Sponsor Investment Shares that were issuable to Moringa Sponsor, L.P., EarlyBirdCapital, Inc., certain of Silexion Therapeutics Ltd.'s pre-Business Combination shareholders and Greenstar, L.P. (incorporated by reference to Exhibit 10.4 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on August 21, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-4_silexion.htm) |
| [10.2](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-5_silexion.htm) | [Amended and Restated Promissory Note, dated August 15, 2024, issued by Silexion Therapeutics Corp (formerly known as Biomotion Sciences) to Moringa Sponsor, L.P. (incorporated by reference to Exhibit 10.5 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on August 21, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-5_silexion.htm) |
| [10.3](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-6_silexion.htm) | [Form of Director and Officer Indemnification Agreement, dated August 15, 2024, by and between Silexion Therapeutics Corp (formerly known as Biomotion Sciences) and each of its executive officers and directors (incorporated by reference to Exhibit 10.6 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on August 21, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-6_silexion.htm) |
| [10.4.1#](https://www.sec.gov/Archives/edgar/data/2022416/000121390024041383/ea020533401ex10-12i_bio.htm) | [Employment Agreement, dated April 1, 2022, by and between Silexion Therapeutics Ltd. and Ilan Hadar (incorporated by reference to Exhibit 10.12.1 to Amendment No. 3 to the Company's Registration Statement on Form S-4 (File No. 333-279281), filed with the SEC on July 12, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000121390024041383/ea020533401ex10-12i_bio.htm). |
| [10.4.2#](https://www.sec.gov/Archives/edgar/data/2022416/000121390024041383/ea020533401ex10-12ii_bio.htm) | [Amendment No. 1 to Employment Agreement, dated May 2024, by and between Silexion Therapeutics Ltd. and Ilan Hadar (incorporated by reference to Exhibit 10.12.2 to Amendment No. 3 to the Company's Registration Statement on Form S-4 (File No. 333-279281), filed with the SEC on July 12, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000121390024041383/ea020533401ex10-12ii_bio.htm) |

---

------

---

| | |
|:---|:---|
| [10.5.1#](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-12_silexion.htm) | [Silexion Therapeutics Corp 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.12 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on August 21, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000121390024071491/ea021197601ex10-12_silexion.htm) |
| [10.5.2#](https://www.sec.gov/Archives/edgar/data/2022416/000117891326002037/zk2635046.htm) | [Amendment to Section 5(b)(i) of the Silexion Therapeutics Corp 2024 Equity Incentive Plan (incorporated by reference to Annex C to Silexion Therapeutics Corp's Proxy Statement on Schedule 14A, filed with the SEC on April 9, 2026)](https://www.sec.gov/Archives/edgar/data/2022416/000117891326002037/zk2635046.htm) |
| [10.6#](https://www.sec.gov/Archives/edgar/data/2022416/000121390024077039/ea021365401ex10-14_silexion.htm) | [Silexion Therapeutics Ltd. 2013 Share Option Plan (incorporated by reference to Exhibit 10.14 to Silexion Therapeutics Corp's Registration Statement on Form S-1 (File No. 333-282017), filed with the SEC on September 10, 2024)](https://www.sec.gov/Archives/edgar/data/2022416/000121390024077039/ea021365401ex10-14_silexion.htm) |
| [10.7](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000143/exhibit_4-1.htm) | [Form of Ordinary Warrant (January 2025 public offering) (incorporated by reference to Exhibit 4.1 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on January 17, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000143/exhibit_4-1.htm) |
| [10.8](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000143/exhibit_4-3.htm) | [Form of Placement Agent Warrant (January 2025 public offering) (incorporated by reference to Exhibit 4.3 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on January 17, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000143/exhibit_4-3.htm) |
| [10.9](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000259/exhibit_10-2.htm) | [Form of Ordinary Share Purchase Warrant (January 2025 warrant exercise inducement transaction) (incorporated by reference to Exhibit 10.2 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on January 30, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000259/exhibit_10-2.htm) |
| [10.10](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000259/exhibit_10-3.htm) | [Form of Placement Agent Warrant (January 2025 warrant exercise inducement transaction) (incorporated by reference to Exhibit 10.3 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on January 30, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000259/exhibit_10-3.htm) |
| [10.11](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002570/exhibit_10-2.htm) | [Form of Ordinary Share Purchase Warrant (July/August 2025 warrant exercise inducement transaction) (incorporated by reference to Exhibit 10.2 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on August 1, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002570/exhibit_10-2.htm) |
| [10.12](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002570/exhibit_10-3.htm) | [Form of Placement Agent Warrant (July/August 2025 warrant exercise inducement transaction) (incorporated by reference to Exhibit 10.3 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on August 1, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325002570/exhibit_10-3.htm) |
| [10.13](https://www.sec.gov/Archives/edgar/data/2022416/000117891325003309/exhibit_4-1.htm) | [Form of Series A Ordinary Share Purchase Warrant (September 2025 public offering) (incorporated by reference to Exhibit 4.1 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on September 12, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325003309/exhibit_4-1.htm) |
| [10.14](https://www.sec.gov/Archives/edgar/data/2022416/000117891325003309/exhibit_4-2.htm) | [Form of Series B Ordinary Share Purchase Warrant (September 2025 public offering) (incorporated by reference to Exhibit 4.2 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on September 12, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325003309/exhibit_4-2.htm) |
| [10.15](https://www.sec.gov/Archives/edgar/data/2022416/000117891325003309/exhibit_4-4.htm) | [Form of Placement Agent Warrant (September 2025 public offering) (incorporated by reference to Exhibit 4.4 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on September 12, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325003309/exhibit_4-4.htm) |
| [10.16](https://www.sec.gov/Archives/edgar/data/2022416/000117891325003385/exhibit_10-1.htm) | [At-The-Market Offering Agreement, dated September 26, 2025, by and between Silexion Therapeutics Corp and H.C. Wainwright & Co., LLC (incorporated by reference to Exhibit 10.1 to Silexion Therapeutics Corp's Current Report on Form 8-K filed with the SEC on September 26, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325003385/exhibit_10-1.htm) |
| [19.1](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000887/exhibit_19-1.htm) | [Insider Trading Policy of Silexion Therapeutics Corp (incorporated by reference to Exhibit 19.1 to Silexion Therapeutics Corp's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000887/exhibit_19-1.htm) |
| [21.1\*](https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/exhibit_21-1.htm) | [List of Subsidiaries](https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/exhibit_21-1.htm) |
| [23.1\*](https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/exhibit_23-1.htm) | [Consent of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, independent registered public accounting firm of Silexion Therapeutics Corp](https://www.sec.gov/Archives/edgar/data/2022416/000117891326000953/exhibit_23-1.htm) |
| [31.1\*](exhibit_31-1.htm)[\*](exhibit_31-1.htm) | [Certification of Silexion Therapeutics Corp's Chief Executive Officer (Principal Executive Officer) pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](exhibit_31-1.htm) |
| [31.2\*](exhibit_31-2.htm)[\*](exhibit_31-2.htm) | [Certification of Silexion Therapeutics Corp's Chief Financial Officer (Principal Financial and Accounting Officer) pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](exhibit_31-2.htm) |
| [32.1\*](exhibit_32-1.htm)[\*\*](exhibit_32-1.htm) | [Certification of Silexion Therapeutics Corp's Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial and Accounting Officer) pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](exhibit_32-1.htm) |
| [97.1](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000887/exhibit_97-1.htm) | [Silexion Therapeutics Corp Policy for Recovery of Erroneously Awarded Compensation (incorporated by reference to Exhibit 97.1 to Silexion Therapeutics Corp's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025)](https://www.sec.gov/Archives/edgar/data/2022416/000117891325000887/exhibit_97-1.htm) |

---

101. INS\*Inline XBRL Instance Document.

101. SCH\*Inline XBRL Taxonomy Extension Schema Document.

101. CAL\*Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101. DEF\*Inline XBRL Taxonomy Extension Definition Linkbase Document.

101. LAB\*Inline XBRL Taxonomy Extension Label Linkbase Document.

101. PRE\*Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104\* Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

\*&nbsp;&nbsp;&nbsp;&nbsp; Filed with the Original 10-K.<br>

\*\* Filed with this Amendment.

\*\*\* Furnished with this Amendment.

# Indicates management contract or compensatory plan, contract or arrangement.

------

SIGNATURES

&nbsp;&nbsp;&nbsp;&nbsp; Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **Silexion Therapeutics Corp** | **Silexion Therapeutics Corp** |
| By: | /s/ Ilan Hadar |
| Name: | Ilan Hadar |
| Title: | Chairman of the Board and Chief Executive Officer |
| Date: | May 19, 2026 |

---

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Name** | **Position** | **Date** |
| /s/ Ilan Hadar | Chairman of the Board and Chief Executive Officer | May 19, 2026 |
| Ilan Hadar | (Principal Executive Officer) |  |
| /s/ Mirit Horenshtein Hadar | Chief Financial Officer | May 19, 2026 |
| Mirit Horenshtein Hadar | (Principal Financial and Accounting Officer) |  |
| /s/ Ruth Alon | Director | May 19, 2026 |
| Ruth Alon |  |  |

---

---

| | | |
|:---|:---|:---|
| /s/ Dror Abramov | Director | May 19, 2026 |
| Dror Abramov |  |  |
| /s/ Avner Lushi | Director | May 19, 2026 |
| Avner Lushi |  |  |
| /s/ Shlomo Noy | Director | May 19, 2026 |
| Shlomo Noy |  |  |
| /s/ Amnon Peled | Director | May 19, 2026 |
| Amnon Peled |  |  |

---

------

## Exhibit 31.1

####  

#### <br>

#### Exhibit 31.1

#### CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
**PURSUANT TO EXCHANGE ACT RULE 13a-14(a)**, **AS ADOPTED PURSUANT TO**

#### SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Ilan Hadar, certify that:

1. I have reviewed this annual report on Form 10-K/A of Silexion Therapeutics Corp (the "**Company** ");

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
 statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of
 the Company as of, and for, the periods presented in this report;

4. The Company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
 over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its
 consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
 financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the
 period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an
 annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting; and

5. The Company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's
 board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record,
 process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.

---

| |
|:---|
| Date: May 19, 2026 |
| /s/ Ilan Hadar |
| Ilan Hadar |
| Chairman of the Board and Chief Executive Officer |
| (Principal Executive Officer) |

---

------

####  

## Exhibit 31.2

####  

#### <br>

#### Exhibit 31.2

#### CERTIFICATION OF THE CHIEF FINANCIAL OFFICER
**PURSUANT TO EXCHANGE ACT RULE 13a-14(a)**, **AS ADOPTED PURSUANT TO**

#### SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Mirit Horenshtein Hadar, certify that:

1. I have reviewed this annual report on Form 10-K/A of Silexion Therapeutics Corp (the "**Company** ");

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
 statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of
 the Company as of, and for, the periods presented in this report;

4. The Company's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
 over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its
 consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
 financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the
 period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an
 annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting; and

5. The Company's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's
 board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record,
 process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.

Date: May 19, 2026

---

| |
|:---|
| /s/ Mirit Horenshtein Hadar |
| Mirit Horenshtein Hadar |
| Chief Financial Officer |
| (Principal Financial and Accounting Officer) |

---

------

![](image3.jpg)

## Exhibit 32.1

------

![](image3.jpg)

#### Exhibit 32.1

#### CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

#### PURSUANT TO RULE 13a-14(b)/RULE 15d-14(b) UNDER THE EXCHANGE ACT

#### AND 18 U.S.C. § 1350

#### AS ADOPTED PURSUANT TO

#### SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Silexion Therapeutics Corp (the "**Company**") on Form 10-K/A for the year ended December 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "**Report**"), we, Ilan Hadar, Chairman of the Board and Chief Executive Officer of the Company, and Mirit Horenshtein Hadar, Chief Financial Officer of the Company, certify, pursuant to Rule 13a-14(b)/Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended and 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

---

| |
|:---|
| Date: May 19, 2026 |
| /s/ Ilan Hadar |
| Ilan Hadar |
| Chairman of the Board and Chief Executive Officer |
| (Principal Executive Officer) |

---

---

| |
|:---|
| /s/ Mirit Horenshtein Hadar |
| Mirit Horenshtein Hadar |
| Chief Financial Officer |
| (Principal Financial and Accounting Officer) |

---

This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "**Exchange Act**"). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the U.S. Securities and Exchange Commission or its staff upon request.

------